Axsome Therapeutics (AXSM) Shares Outstanding (Weighted Average) (2015 - 2026)

Axsome Therapeutics has disclosed Shares Outstanding (Weighted Average) across 12 years of filings, most recently posting $51.2 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $51.2 million, up 4.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.2 million (up 4.76% YoY), and the FY2025 annual result was $49.7 million, up 3.83% from the prior year.
• Shares Outstanding (Weighted Average) came in at $51.2 million for Q1 2026 at Axsome Therapeutics, up from $79220.0 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $51.2 million in Q1 2026 to a low of $50796.0 in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $45.4 million (2023), against an average of $40.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 89326.75% in 2023 and tumbled 99.83% in 2025, its largest moves.
• Axsome Therapeutics' Shares Outstanding (Weighted Average) stood at $50796.0 in 2022, then surged by 89326.75% to $45.4 million in 2023, then advanced by 5.48% to $47.9 million in 2024, then sank by 99.83% to $79220.0 in 2025, then jumped by 64528.06% to $51.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $51.2 million (Q1 2026), $79220.0 (Q4 2025), and $49.4 million (Q3 2025), per Business Quant data.